What's new? Log in Free sign up

Procept BioRobotics (PRCT) News and press releases

Company Profile

News

From Benzinga Pro

Expert Ratings for PROCEPT BioRobotics

Analyst Ratings

Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $55

News, Price Target, Analyst Ratings

Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $58 to $55.

Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $43

News, Price Target, Analyst Ratings

Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $52 to $43.

Expert Ratings for PROCEPT BioRobotics

Analyst Ratings

Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $52

News, Price Target, Analyst Ratings

Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $49 to $52.

Press releases

From Benzinga Pro

PROCEPT BioRobotics Corp. to Present at the 41st Annual J.P. Morgan Healthcare Conference

News, Press Releases

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in